Original news and analysis on international IP policy
Should national drug control bodies grant marketing licences to generic medicine companies only if their products do not possibly infringe existing patent rights? Yes, German pharmaceutical company Bayer told the High Court of Delhi last week when the court heard arguments in an ongoing court case on patent linkage.
The number and intensity of debates over the role of intellectual property rights in public health is set to increase in 2009.
New leadership and new mandates for key intergovernmental organisations implemented last year have created opportunity for change. And while old debates over the balance between IP rights and access to health products are not going away, this year will see more exploration at the intergovernmental level of different systems to stimulate innovation.
Key players in the biotechnology industry are leading an effort to obtain global approval processes for generic biological medicines, which experts say could provide cheaper access to costly but widely prescribed and promising treatments.
布鲁塞尔 - 全球公共卫生活跃分子声称，欧盟执意要在一系列自由贸易协议中添加有关医药专利的强硬规定将会妨害发展中国家获得医药。
ابروكسل- إن الجهود التي يبذلها الاتحاد الأوروبي لإدراج أحكام حول براءات المستحضرات الصيدلانية في سلسلة من اتفاقات التجارة الحرة التي يتفاوض حولها قد تشكل تهديدا على إمكانية الحصول على الأدوية في البلدان النامية، على حد قول الناشطين في مجال الصحة العامة على الصعيد العالمي.
BRUXELLES - Selon certains activistes de la santé publique mondiale, les efforts de l’Union européenne (UE) pour intégrer des dispositions sur les brevets pharmaceutiques dans un certain nombre d’accords de libre échange en cours de négociation pourraient mettre en péril l’accès aux médicaments dans les pays en développement.
BRUSELAS- Los esfuerzos de la Unión Europea para introducir disposiciones firmes en materia de patentes farmacéuticas en una serie de acuerdos de libre comercio que está negociando podrían poner en peligro el acceso a los medicamentos en los países en desarrollo, según han afirmado activistas de la salud pública a nivel mundial.
As the United States battles an economic meltdown, items like economic stimulus and home foreclosure relief are taking centre stage. Congress also is still working to confirm President Obama's nominees. But once those items are dealt with, issues such as patent reform and intellectual property enforcement are expected to be hot-button items once again.
Leading international public health advocates have sent letters to the heads of the World Health Organization and World Trade Organization calling on them to act to prevent possible circumvention of international trade rules for intellectual property rights relating to shipments of legal generic drugs bound for developing countries.
The effort to tackle digital piracy is likely to remain the most contentious intellectual property issue in Europe this year. It will be joined by debates on copyright term extension, IP provisions in trade agreements, and an ongoing discussion of patent policy in Europe.
BRUSSELS - Efforts by the European Union to insert strong provisions on pharmaceutical patents in a series of free trade agreements it is negotiating could imperil access to medicines in developing countries, global public health activists have alleged.
As part of trade talks being conducted with India, Colombia, Peru and a regional grouping in south-east Asia, EU officials have proposed that drug-makers should benefit from a robust intellectual property regime. National regulatory authorities in the countries concerned would be prevented for lengthy periods from using data provided by a company that holds a drug patent in order to authorise a generic version of that medicine.
With patent reform expected to be introduced sooner rather than later in this 111th United States Congress, calculating damages for infringement remains one of the main sticking points.